The State of the AI Debate

Nathaniel Whittemore (0:00)

The next era of the AI debate is officially upon us. On the one hand, you have President Trump calling for a new AI force, as well as suggesting his own rebrands of the entire industry. On the other, you have regulators and politicians all around the country proposing AI kill switches and new bills and changes to data center policy. And behind all of that, you have the lurking question of China. If China isn't on board with any sort of pause or pacing the frontier, do those actions even matter? This week, Chinese President Xi Jinping is in Washington. And already, the trade delegations have been discussing AI. So will we actually see progress on some of these questions? Or will the state of the AI debate remain firmly divided between these two very different countries?

The AI Daily Brief is a daily podcast and video about the most important news and discussions in AI.

Welcome back to the AI Daily Brief Headlines edition, all the daily AI news you need in around five minutes. We kick off today with Anthropic punting their planned blockbuster IPO into November, although insiders say the delay has nothing to do with AI safety. The Wall Street Journal reports that Anthropic will not, in fact, go public this month or next as originally planned. However, sources said the decision to delay was made before CEO Dario Amade called for an AI slowdown. Instead, Anthropic's advisors have said the delay would allow them to share third quarter financials, which are expected to be strong. The information confirmed the reporting, adding that Anthropic has not begun meeting with Wall Street analysts and institutional investors. These road shows usually take place around a month before the IPO. However, some potential investors have been meeting with Anthropic as part of so-called testing the waters meetings. Leaking a few financial details, sources said that Anthropic has gone from spending $2.30 for every dollar in revenue in Q2 of last year to being slightly profitable on that basis in Q2 of this year. That would line up with recent reporting from the Financial Times, which said Anthropic claimed they had positive operating income after stripping out stock-based comp. That report repeated a claim that gross margins were above 80 percent if you strip out revenue sharing deals and the cost of model training. Industry critics were perhaps unsurprisingly extremely negative on this framing, suggesting that stripping away major cost to get to profitability on paper is not a great indication of financial health. This is one potential issue with the Anthropic IPO as disclosure documents will give investors their first look at unadjusted numbers. The information wrote that some investors also walked away from meetings with the impression that profitability would be short lived. The company has signed a ton of new data center deals that will start to add structural cost over the coming quarters. Kevin Chu of Interconnected Capital suggested the market could have a difficult time signing a blank check commenting, Anthropic going public means it is elevating itself to the entire financial market, making it more palatable for them to get different options of financing. But the public market community still wants to trust the fact that Anthropic can fund its own capital expenditure, and that debt is a bridge to that, not that the borrowing has no end in sight. That's the problem the entire AI complex has right now.

The New York Times reported that Anthropic said they're on track to reach $100 billion in annualized revenue by the end of the year, up from $65 billion at the end of July.

What's more, beyond the numbers, some on Wall Street are beginning to view AI safety risk as a market risk. Former NASDAQ executive-turned-consultant Karen Snow said that following the calls for a slowdown, the Anthropic IPO, quote, went from being a no-brainer to not being a no-brainer. She added, The markets can be finicky and sentiment has shifted a bit on AI. The issue is there's a bit of a gray cloud over AI right now. To that end, Anthropic could be delaying their IPO in order to get a new model out the door and try to shift the narrative from safety to progress. AI leakers are starting to report sightings of new Sonnet, Opus and Fable models and stealth testing, meaning we could see a complete model overhaul in the coming weeks. It seems Anthropic are still on track for an IPO by the end of the year.

Maybe the even more interesting discussion around Anthropic, however, is that the company has reportedly set up a wet lab in the Bay Area to begin biological experiments. Reuters reports that Anthropic has quietly established their own biology lab to conduct in-house research. Anthropic's head of life sciences, Eric Kadore-Abrams told Reuters, We believe that to do biology, the final test is still and will be for a while in real lab work. We absolutely are doing that today. He said that the lab operates similarly to other biotech labs in the Bay Area. And while Anthropic didn't divulge exactly what they're working on, they did note the focus was on fundamental biology rather than drug discovery.